

Remarks

Reconsideration of this Application is respectfully requested.

The Examiner requested on February 4, 2003, that claims 3, 15, 16, and 22 be amended by canceling the reference to "N-morpholinyl", "N-pyrrolidinyl", and "N-piperazinyl" as definitions for R₁₀, and that copies of the references listed on Form PTO-1449 resubmitted on May 9, 2002, be resubmitted.

During a telephone conference on February 5, 2003, the Examiner agreed that claim 15 can be amended by canceling the phrase "selected from the group consisting of N-morpholinyl, N-pyrrolidinyl, and N-piperazinyl" from the definitions of R₁₀, leaving the term "heterocycle" as a definition for R₁₀.

During a telephone conference of February 13, 2003, it was brought to the Examiner's attention that Applicants wish to amend claim 17, directed to pharmaceutical compositions, to be dependent also on independent claims 22 and 25 in addition to claims 1 and 16. Furthermore, the Examiner indicated that he is willing to rejoin and consider the method claims 18-21, canceled in the previous Amendment of November 27, 2002, as long as they are specifically adapted to the allowable compounds and they are amended in such a way that no § 112, paragraph issues rise. Specifically, the Examiner requested the deletion of the term "preventing" from all the method claims.

Applicants resubmitted the references originally submitted along with Form PTO-1449 accompanying Applicants' Information Disclosure Statement, filed December 13, 2001 and resubmitted by facsimile on May 9, 2002, on February 13,

2003 via hand carry. Applicants respectfully request the Examiner to provide a copy of the initialed and signed PTO-1449 forms.

Claims 3, 15, 16, 17, and 22 are sought to be amended, and new claims 28-31 are sought to be added. Claims 3, 15, 16, and 22 have been amended by amending the definitions for R₁₀ as requested by the Examiner. Applicants submit that no new matter has been introduced by this amendment since deletion of individual members of a Markush expression does not constitute new matter. *See In re Johnson and Farnham*, 558 F.2d 1008, 1019, 194 U.S.P.Q. 187, 196 (CCPA 1977). Claim 17 has been amended by amending the dependencies. Specifically, claim 17 has been amended to be dependent on all independent compound claims 1, 16, 22, and 25. Support for this amendment can be found in the original specification and claims as filed.

New claims 28-31 find support in the original claims 18-21. New claims 28-31 are specifically adapted to the allowable compounds. Further, none of claims 28-31 include the term "preventing."

These changes are believed to introduce no new matter, and their entry is respectfully requested. Upon entry of the foregoing amendment, claims 1-10, 15-17 and 22-31 are pending in the application, with claims 1, 16, 22 and 25 being the independent claims.


Conclusion

All of the stated grounds of objection and rejection have been properly traversed, accommodated, or rendered moot. Applicants therefore respectfully request that the Examiner reconsider all presently outstanding objections and rejections and that they be withdrawn. Applicants believe that a full and complete reply has been made to the outstanding issues raised by the Examiner and, as such, the present application is in condition for allowance. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Supplemental Amendment and Reply is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



John M. Covert
Attorney for Applicants
Registration No. 38,759

Date: Feb. 14, 2003

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Version with markings to show changes made


New claims 28-31 have been added.

Claims 3, 15, 16, 17, and 22 have been amended as follows:

3. (Once Amended) A compound of claim 2, wherein R₁₀ is selected from the group consisting of C₁₋₆ alkyl, C₂₋₆ alkenyl, OR₁₀, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, C₂₋₆ alkenylamino, and di(C₁₋₆)alkylamino(C₂₋₆)alkenyl[, N-morpholinyl, N-pyrrolidinyl, and N-piperazinyl].

15. (Three Times Amended) A compound of claim 1, wherein:
R₁ is C(O)R₁₀, CH₂C(O)R₁₀, or SO₂R₁₀;
X is O or S;
R₁₀ is amino, optionally substituted C_{1-C₆} alkyl, or a heterocycle [selected from the group consisting of N-morpholinyl, N-pyrrolidinyl and N-piperazinyl];
R₂, and R₃ are independently hydrogen, C_{1-C₆} alkyl, C_{1-C₆} alkylthio or C_{1-C₆} alkylsulfanyl,
R₅ and R₆ are as defined in claim 1, and
R₇ and R₈ are independently selected from the group consisting of hydrogen, halo, halo(C_{1-C₆})alkyl, C_{1-C₆} alkyl, hydroxy(C_{1-C₆})alkyl, amino(C_{1-C₆})alkyl, carboxy(C_{1-C₆})alkyl, alkoxy(C_{1-C₆})alkyl, nitro, amino, C_{1-C₆} acylamino, amide, hydroxy, thiol, C_{1-C₆} acyloxy, C_{1-C₆} alkoxy, carboxy, carbonylamido and C_{1-C₆} alkylthiol.

16. (Three Times Amended) A compound of Formula I:




I

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is O or S;

Het is




R₁ is C(O)R₁₀, CH₂C(O)R₁₀, or SO₂R₁₀ wherein R₁₀ is amino[,] or alkyl, [N-morpholinyl, N-pyrrolidinyl or N-piperazinyl], all of which are optionally substituted;

R₂ and R₃ are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ alkylthio or C₁-C₆ alkylsulfinyl; and

R₅, R₆, R₇ and R₈ are independently selected from the group consisting of hydrogen, halo, halo(C₁-C₆)alkyl, C₁-C₆ alkyl, hydroxy(C₁-C₆)alkyl, amino(C₁-C₆)alkyl, carboxy(C₁-C₆)alkyl, alkoxy(C₁-C₆)alkyl, nitro, amino, C₁-C₆ acylamino, amide, hydroxy, thiol, C₁-C₆ acyloxy, C₁-C₆ alkoxy, carboxy, carbonylamido and C₁-C₆ alkylthiol.

17. (Once Amended) A pharmaceutical composition, comprising the compound of any one of claims [claim] 1, or 16, 22, or 25 and a pharmaceutically acceptable carrier.

22. (Three Times Amended) A compound of Formula I:




I

or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein

X is O or S;

Het is



R₁ is C(O)R₁₀, wherein R₁₀ is amino[, N-morpholinyl, N-pyrrolidinyl or N-piperazinyl, all of which are optionally substituted];

R₂ and R₃ are independently hydrogen, C₁-C₆ alkyl, C₁-C₆ alkylthio or C₁-C₆ alkylsulfinyl; and

R₅, R₆, R₇ and R₈ are independently selected from the group consisting of hydrogen, halo, halo(C₁-C₆)alkyl, C₁-C₆ alkyl, hydroxy(C₁-C₆)alkyl, amino(C₁-C₆)alkyl, carboxy(C₁-C₆)alkyl, alkoxy(C₁-C₆)alkyl, nitro, amino, C₁-C₆ acylamino, amide, hydroxy, thiol, C₁-C₆ acyloxy, C₁-C₆ alkoxy, carboxy, carbonylamido and C₁-C₆ alkylthiol.

Applicants: Hogenkamp *et al.*

Due Date: None

Art Unit: 1626

Examiner: Shameem, G.

Docket: 1861.1270001

Atty: JMC/THN

Application No.: 09/814,123

Filed: March 22, 2001

For: Aryl Substituted Pyrazoles, Triazoles and Tetrazoles, and the Use Thereof

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF Cover Letter;
2. Supplemental Amendment and Reply; and
3. One (1) return postcard.

Applicants: Hogenkamp *et al.*

Due Date: None

Art Unit: 1626

Examiner: Shameem, G.

Docket: 1861.1270001

Atty: JMC/THN

Application No.: 09/814,123

Filed: March 22, 2001

For: Aryl Substituted Pyrazoles, Triazoles and Tetrazoles, and the Use Thereof

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following documents:

1. SKGF Cover Letter;
2. Supplemental Amendment and Reply; and
3. One (1) return postcard.

RECEIVED
TECH CENTER 1600/2900
03 FEB 14 PM 3:27

Via Hand Carry
Group Art Unit 1626
Examiner G. Shameem

February 14, 2003

SKGF_DCI:102711.1

Please Date Stamp And Return To Our Courier



ATTORNEYS AT LAW

Robert Greene Sterne
Edward L. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michelle A. Cloboda
Michael B. Ray
Robert E. Solohl
Eric K. Steffes
Michael O. Lee
Steven R. Ludwig
John M. Coveri
Linda E. Alcam
Robert C. McConig
Lawrence B. Burghardt
Donald J. Featherstone
Michael V. Messinger

Andrea U. Kim
Tawnya I. Shea, Jr.
Patrick F. Garret
Jeffrey I. Hevner
Heidi L. Konz
Edward W. Yee
Albert L. Foss
Donald R. Banowitz
Peter A. Indenbirken
Molly A. McCall
Terria U. Medler
Jeffrey S. Werner
Kendrick P. Petersen
Vincent L. Capusano
Albert J. Fusillo, Jr.
Elkosa Ellison Floyd
Thomas C. Fuhs
Brian J. Del Buono

Virgil Lee Beasom*
Kimberly N. Redick
Theodore A. Wood
Elizabeth J. Haimes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cunningham
Christina M. Lederer
Rita Lynn Przygocki
Iace Shershonovich*
Lawrence J. Carroll*
George S. Barthmesser
Donald A. Klein*
Rodney G. Maze
Jason D. Eisenberg
Matthew A. Specht
Andrea L. Kamage
Tracy L. Miller*

Jon E. Wright*
LuAnne M. Turlock*
Registered Patent Agents:
Karen B. Matlowicz
Nancy J. Letch
Ann L. Summerfield
Helene C. Carlson
Gaby L. Longsworth
Matthew J. Dowd
Aaron L. Schwartz
Angélique G. Uy
Boris A. Matlowitz
Mary B. Fung
Kathrina T. Pe
Bryan L. Steltz
Robert A. Schwartzman
John J. Figueroa

Timothy A. Doyle
Jennifer R. Matlowicz
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
W. Brian Edge
Senior Counsel:
Samuel L. Fox
Kenneth C. Bass (II)
Lisa A. Dunbar

*Admitted only in Maryland
+Admitted only in Virginia
#Admitted only in Texas
\$Practice Limited to Federal Agencies

February 14, 2003

WRITER'S DIRECT NUMBER:
(202) 772-8673
INTERNET ADDRESS:
SKOVERT@SKGP.COM

Via Facsimile

Commissioner for Patents
Washington, D.C. 20231

Confirmation Copy Via Hand Carry
Group Art Unit 1626
Examiner G. Shameem

Re: U.S. Utility Patent Application
Appl. No. 09/814,123; Filed: March 22, 2001
For: **Aryl Substituted Pyrazoles, Triazoles and Tetrazoles, and the Use
Thereof**
Inventors: HOGENKAMP *et al.*
Our Ref: 1861.1270001/JMC/THN

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Supplemental Amendment and Reply; and
2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
February 14, 2003
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

SERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


John M. Covert
Attorney for Applicants
Registration No. 38,759

Enclosures

SKGF_DCI:102710.1